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Abstract
Problems with attention and short-term learning and memory are commonly reported after mild 
traumatic brain injury (mTBI). Due to the known relationships between α-synuclein (SNCA), 
dopaminergic transmission, and neurologic deficits, we hypothesized that SNCA polymorphisms 
might be associated with cognitive outcome after mTBI. A cohort of 91 mTBI patients one month 
after injury and 86 healthy controls completed a series of cognitive tests assessing baseline 
intellectual function, attentional function, and memory, and was genotyped at 13 common single 
nucleotide polymorphisms (SNPs) in the SNCA gene. Significant differences in two memory 
measures (p = 0.001 and 0.002), but not baseline intellectual function or attentional function tasks, 
were found between the mTBI group and controls. A highly significant protective association 
between memory performance and SNCA promoter SNP rs1372525 was observed in the mTBI 
patients (p = 0.006 and 0.029 for the long and short delay conditions of the California Verbal 
Learning Tests, respectively), where the presence of at least one copy of the A (minor) allele was 
protective after mTBI. These results may help elucidate the pathophysiology of cognitive 
alterations after mTBI, and thus warrant further investigation.
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Introduction
Mild traumatic brain injury (mTBI) is a major public health problem affecting over 1.27 
million Americans every year [1]. While many mTBI patients recover without significant 
long-term consequences, some individuals continue to have persistent symptoms, including 
problems with memory, attention, processing speed, and executive function [2]. Patients 
with seemingly similar degrees of injury often display differing severity of deficits, leading 
our group and others to postulate that polymorphisms in genes modulating the neural 
response to trauma may influence clinical outcome after mTBI [3, 4].
Alterations in dopaminergic and other catecholaminergic signaling systems have been 
hypothesized to play a role in persistent cognitive complaints and deficits after TBI: striatal 
dopamine levels have been shown to decrease post-injury, and the clinical treatment of TBI 
involves increasing dopaminergic neurotransmission [5, 6]. Studies in both mice and humans 
have demonstrated abnormal dopamine transport and D2 receptor binding in response to 
varying severities of TBI [7, 8]. Furthermore, it has been recently shown that mTBI patients 
performing working memory tasks have an altered response to the dopamine D2 receptor 
agonist bromocriptine as compared to healthy controls [9].
Because of this putative role of dopaminergic pathways in mTBI, genes that influence 
dopaminergic function are attractive candidates for study. One candidate of interest is the 
gene for α-synuclein (SNCA), a member of the synuclein family of proteins that has been 
implicated in the pathogenesis of multiple neurologic diseases including Parkinson’s disease 
(PD), multiple system atrophy, and Lewy body dementia [10]. In early functional studies by 
Abeliovich et al., α-synuclein knockout-mice showed a reduction in striatal dopamine and 
attenuated dopamine-dependent response to amphetamine without neuronal degeneration, 
suggesting a regulatory role of α-synuclein in dopaminergic neurotransmission [11]. α-
Synuclein has since been further implicated as a regulator of dopamine biosynthesis and 
availability through interactions with tyrosine hydroxylase [12]; as a determinant of the 
density of dopaminergic neurons in the substantia nigra [13]; and as a mediator of long-
lasting increase in neurotransmitter release [14]. Polymorphisms in the SNCA gene are well-
documented genetic risk factors for PD [15], a disease pathologically characterized by loss 
of midbrain dopaminergic neurons, and whose clinical features include not only 
extrapyramidal motor symptoms, but often also impairment of memory and executive 
functions as is commonly seen in traumatic brain injury. Outside of PD, SNCA 
polymorphism associations have not been well elucidated.
Given the relationships between dopamine, mTBI, and SNCA, we hypothesized that 
polymorphisms in SNCA might influence cognitive performance in mTBI patients.
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Methods
Participants
A cohort of 91 consecutive patients with mTBI was recruited from a Level 1 trauma center 
emergency department using American Congress of Rehabilitation Medicine criteria for 
mild TBI [16]. Specifically, mTBI was defined as an initial Glasgow Coma Scale (GCS) 
score of 13–15 when available and/or duration of loss of consciousness not exceeding 30 
minutes. mTBI participants were studied approximately one month after injury. A total of 86 
normal controls were evaluated. One cohort of healthy control subjects (n=38) was recruited 
specifically for this study through advertisements. Demographic, cognitive, and genotype 
data from additional healthy control subjects (n=48) studied by our group as part of 
previously published breast cancer and aging studies [17, 18] were obtained. Exclusion 
criteria of a history of other neurological disorders, substantial systemic medical illness, or 
current DSM-IV axis I psychiatric diagnosis disorder with the exception of substance abuse 
based on the Structured Clinical Interview for DSM-IV [19] resulted in the elimination of 
four mTBI subjects. The study protocol and informed consent were approved by the 
Dartmouth College Committee for the Protection of Human Subjects. Written informed 
consent was obtained from all participating subjects. Over 95% of the TBI and control 
groups were Caucasians of European descent.
Cognitive measures
All cognitive tests were determined prior to analyzing the data. The Wide-Range 
Achievement Test (WRAT) reading subtest [20] was used to estimate baseline level of 
general intellectual function. Simple Reaction Time, Vigilance, and Distractibility conditions 
of the Continuous Performance Test (CPT) were used as measures of attentional function 
[21]. The Short Delay (SD) and Long Delay (LD) conditions of the California Verbal 
Learning Test (CVLT) were selected as the primary outcome measures of memory [22].
Genotyping and characterizing the SNCA locus
DNA was purified from peripheral blood using QIAGEN’s blood mini kit (QIAGEN, 
Alameda, CA). Genotyping was done using a custom made 3600 SNP microarray gene chip 
(Affymetrix, Inc., Santa Clara, CA) as previously described [4]. This study is based on the 
13 SNCA polymorphisms included in that array.
Haploview [23] and the NCBI Homo sapiens Annotation Release 105 were used to 
characterize and study SNCA polymorphisms. P-values for Hardy-Weinberg equilibrium 
(HWE) and minor allele frequency were obtained based on both chi-squared and exact test 
analysis. In addition, linkage disequilibrium (r2) was analyzed for all combinations of SNPs.
Statistical analyses
Between-group differences in demographic characteristics were examined by t-tests or chi-
square tests for continuous or categorical variables, respectively. Each of the allele variables 
was summarized as a factor variable with two levels assuming a dominant genetic model (at 
least one copy of the minor allele vs no copies of the minor allele). Genetic group 
differences for cognitive measures were analyzed by analysis of covariance (ANCOVA) with 
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diagnosis, the allele variable, and the interaction between allele and diagnosis included in 
the model, covarying for age and gender; education was not included in the final model 
because of a significant correlation with both the independent variable and other covariates. 
Significance tests were examined for the main effects of diagnosis and allele status, and for 
the interaction between allele and diagnosis. Significant p-values for polymorphisms and 
cognitive measures were adjusted for multiple comparisons using the Benjamini and 
Hochberg false discovery rate (FDR) method, using an FDR of 0.10 [24]. All analysis was 
performed and repeated using Excel Data Analysis Toolkit, SPSS, and Stata.
Polymorphism comparison between mTBI and PD
PDGene contains a comprehensive, unbiased and regularly updated synopsis of genetic 
association studies performed in PD [15]. Meta-analyses were obtained for all characterized 
polymorphisms in the SNCA gene, and odds ratios and confidence intervals were averaged 
between all studies available. This data was downloaded on 1/10/2015 and compared to the 
results from our mTBI study.
Results
Demographics
The population characteristics of the healthy control and mTBI groups are summarized in 
Table 1. Due to the nature of the control cohorts (38 subjects recruited specifically for this 
study, 27 subjects from an aging study, and 21 subjects from a breast cancer study), there 
were significant differences in age, education, and sex between control and mTBI groups: all 
additional statistical analysis was therefore done co-varying for these three factors. However, 
the mTBI patients and the control subjects recruited specifically for this study and the mTBI 
patients were balanced for age, education and sex, and there were no substantive differences 
in the results of this study when only those control subjects were considered (p>0.05). The 
mTBI group had a mean (SD) GCS score of 14.8 (0.550), a post-traumatic amnesia duration 
of 5.36 (7.18) hours, and loss of consciousness of 5.13 (7.58) minutes, a cognitive profile 
consistent with mTBI. The mean injury-to-testing time was 39.5 (15.8) days.
Cognitive measures
Cognitive results are included in Table 1. There was no significant difference in baseline 
intellectual function as estimated by the WRAT reading score, or attentional function as 
measured by the Continuous Performance Tasks (CPT): Simple Reaction Time, Vigilance, 
and Distractibility. Significant performance differences were found between the two groups 
on the California Verbal Learning Test (CVLT) Short Delay and Long Delay free recall 
conditions (p=0.001 and p=0.002, respectively). Therefore, all further analyses were 
performed using both CVLT (SD and LD) conditions. These findings are consistent with 
previous studies, which confirm no difference in the WRAT reading scores of mTBI patients 
and controls [3, 25] but a significant difference in both CVLT-SD and LD[3, 4, 26]. 
Additionally, no significant differences were found between memory performance (CVLT-
LD and CVLT-SD) of the volunteer, breast cancer study, and aging study control groups 
(p>0.05).
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Genetic analysis
Based on the chi-square and exact test analyses, the analyzed SNPs were all in Hardy-
Weinberg equilibrium (p > 0.356), with minor allele frequencies greater than 0.17. The 
default setting in Haploview showed strong linkage disequilibrium between some of the 
SNPs (data not shown).
Effects of genotype on memory performance
The effects of genotype on memory performance on the CVLT SD and LD trials are 
summarized in Table 2. Using an autosomal dominant inheritance model for analysis, the 
most significant association was of the promoter polymorphism rs1372525 in mTBI patients 
with the CVLT SD and LD trials (p = 0.029 and 0.006, respectively). The G/G genotype was 
associated with poorer memory performance phenotype in mTBI patients (n=30), while 
having at least one copy of the A allele was shown to exert a protective effect (n=61) (Figure 
1a). In contrast, no similar relationship was found when comparing attentional function 
scores (e.g. CPT: Simple Reaction Time and Vigilance) with genotype (Figure 1b), 
suggesting a memory-specific effect. A similar pattern was observed in subjects with the 
polymorphism rs356219 (SD and LD), rs1023777 (SD and LD), and rs2301134 (SD only) 
(Table 2).
Because of the high degree of linkage disequilibrium between the polymorphisms studied, 
the analyses were repeated covarying for the most significant SNP, rs1372525. The 
previously noted significant associations for rs356219 and rs102377 and CVLT LD were no 
longer significant in the new model (p = 0.195 and 0.882, respectively), and their association 
with CVLT is presumably due to linkage disequilibrium with rs1372525. Similar results 
were obtained for the CVLT SD.
In order to be sure that the differences between the G/G subjects and A allele subjects were 
not due to chance differences in injury severity, the analyses were repeated across 
polymorphism groups for duration of loss of consciousness (LOC), duration of post-
traumatic amnesia (PTA), and GCS score. For rs1372525, no significant differences were 
found between the two groups for LOC (p = 0.710), PTA (p = 0.624), and GCS (p = 0.733), 
thus ruling out the impact of injury severity on our findings.
Comparison of SNPs associated with PD and those associated with memory difficulties 
after mTBI
Because of the importance of SNCA in PD, we evaluated whether or not those 
polymorphisms found to have protective effects on memory after mTBI are also implicated 
in PD pathophysiology. Each of the polymorphisms examined in this study has been 
included in four or more PD genetic association studies, and meta-analysis of those studies 
is available in PDgene. Combining PDGene data downloaded on 1/10/2015 with our own 
polymorphism data, we found that there was no significant relationship between the 
polymorphisms most significantly associated with improved cognitive performance after 
mTBI and the polymorphisms associated with PD (p>0.05; Table 2). Specifically, 
rs1372525, the most significant polymorphism in the mTBI study, has not been associated 
with the risk of PD (OR ~1; Table 2).
Shee et al. Page 5
Neurosci Lett. Author manuscript; available in PMC 2017 September 06.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Discussion
The specific pathophysiology responsible for problems with cognitive outcomes after mTBI 
is not well understood, although substantial evidence suggests a role for altered 
dopaminergic neurotransmission. SNCA is an attractive candidate for study in this context 
because of its role in PD, a disease caused by death of dopaminergic neurons. We 
hypothesized that polymorphisms in SNCA might also be associated with measures of 
cognitive outcome following mTBI.
Utilizing a cohort of 95 mTBI patients and 86 normal controls, we found that there are 
SNCA polymorphisms associated with cognitive outcomes related to memory function after 
mTBI. Specifically, we observed a strong association between the promoter polymorphism 
rs1372525 and a protective memory phenotype after mTBI, such that patients having at least 
one copy of the A allele performed significantly better for free memory recall as measured 
by the CVLT-SD and LD trials. All other polymorphism associations could be accounted for 
by linkage disequilibrium with rs1372525. We note with interest that this polymorphism is 
not associated with the risk of PD, and polymorphisms which are associated with risk of PD 
were not associated with a better or worse cognitive outcome in this mTBI cohort. This lack 
of association is supported by a recent study by Guella et al., who show that SNCA 
polymorphisms associated with cognitive defects in PD spectrum disorders are unrelated to 
those associated with risk for PD [27].
There are multiple potential mechanisms for the protective effect of rs1372525 and other 
SNCA promoter polymorphisms on memory. The first mechanism is through altered 
dopaminergic neurotransmission mediated by polymorphism-mediated changes in gene 
expression. It is well described that learning and memory are strongly dependent on 
dopamine neurotransmitter activity, particularly in the prefrontal cortex [28], hippocampus 
[29], and striatum [30]. Furthermore, SNCA promoter polymorphisms have been previously 
linked to altered α-synuclein expression in humans [31]. It is therefore possible that the 
protective mechanism of rs1372525 and other SNCA promoter polymorphisms involves 
regulation of α-synuclein expression, which could alter dopamine release and downstream 
activity to levels optimal for memory functions. An alternative possible mechanism by 
which specific SNCA polymorphisms may exert a protective effect on memory after mTBI 
involves decreasing α-synuclein aggregation. It has been shown that brain injury impairs 
axonal transport and induces inflammatory cascades, leading to the accumulation of α-
synuclein and subsequent impairment of neurological and behavioral functions [32]. 
Interestingly, it has been shown that ‘risk’ polymorphisms in the 3’ region of SNCA leads to 
alternative splicing with increased relative levels of splice variant SNCA112-mRNA, 
resulting in enhanced α-synuclein aggregation [33]. Therefore, rs1372525 and other SNCA 
polymorphisms could exert neuroprotective effects post-mTBI by decreasing α-synuclein 
accumulation through alternative splicing or other means.
There are a few limitations to this study. First, cognitive change after mTBI is a complex, 
multifactorial process. Our significant results did not account for other factors that may play 
a role in cognitive recovery, such as post-injury treatment and psychosocial factors. Second, 
the subjects in this study are mostly of northern European Caucasian descent, and the study 
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needs to be repeated with other populations. Third, the control and mTBI populations were 
significantly different in their age, gender, and education levels. Although their estimated 
baseline intellectual function did not demonstrate a significant difference and these variables 
were covaried for in analyses, this study should ideally be repeated with mTBI cohorts with 
a larger female population. Finally, the sample size used in this study was limited and should 
be repeated in other mTBI cohorts.
Despite these limitations, our study provides novel evidence for a role of SNCA in memory 
performance post-mTBI. To our knowledge, this is the first report describing a direct link 
between α-synuclein and cognitive outcome after mTBI. Our significant results warrant 
future analysis, such as study in more severe cases of traumatic brain injury, interaction with 
post-injury treatment and psychosocial factors, and generalizability to other population 
cohorts.
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Highlights
• Patients with mTBI have significantly decreased memory performance 
one month after injury
• Protective association between memory performance and SNCA 
promoter polymorphism rs1372525
• Less significant SNCA polymorphisms attributed to linkage 
disequilibrium with rs1372525
• Protective effect of rs1372525 not related to risk for Parkinson’s 
Disease
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Figure 1. Effect of rs1372525 allele status on cognitive outcomes
A. Memory measures. Effect of rs1372525 genotype on the number of words recalled (Short 
and Long Delay free recall measures of the California Verbal Learning Test) in the mild 
traumatic brain injury (mTBI) group and the control group. Higher values indicate better 
memory performance. Statistically significant differences were found in the mTBI group 
between the G/G homozygotes (n = 61) and the groups with an A allele (n = 30). Error bars 
represent standard error. *p=0.029 **p=0.006
B. Attentional function measures. Effect of rs1372525 genotype as measured by CPT Simple 
Reaction Time and Vigilance Accuracy in the mild traumatic brain injury (mTBI) group and 
the control group. No statistically significant changes were detected (p>0.05). Error bars 
represent standard error.
Shee et al. Page 11
Neurosci Lett. Author manuscript; available in PMC 2017 September 06.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Shee et al. Page 12
Table 1
Study population demographics and cognitive performance measures
Demographic characteristics (Age, Gender, Education, Mother’s education, and Father’s education) of the 
mTBI patients and healthy controls. Cognitive performance measures (WRAT, Simple Reaction Time, 
Vigilance, and Distractibility conditions of the CPT, and Short and Long Delay Free Recall conditions of the 
CVLT) of the mTBI patients and healthy controls.
n 91 86
Age, years 33.7 (13.7) 47.9 (10.2) <0.001
Male, gender 56 (61.5%) 27 (31.8%) <0.001
Education years 14.3 (2.63) 15.9 (2.38) <0.001
Mother's education,
years
13.7 (2.55) 13.4 (2.94) 0.367
Father's education,
years
14.5 (3.52) 13.8 (3.64) 0.254
WRAT Reading
Standard Score
106.8 (9.84) 105.9 (9.04)* 0.595
Simple Reaction Time
Number Correct (CPT)
28.9 (2.23) 28.9 (1.20)** 0.931
Vigilance Number
Correct (CPT)
28.9 (2.32) 28.4 (2.94)** 0.308
Distractability
Number Correct (CPT)
26.0 (6.30) 27.4 (2.94)** 0.193
Short Delay Free
Recall (CVLT)
10.9 (3.30) 12.7 (2.21) 0.001
Long Delay Free
Recall (CVLT)
11.4 (3.14) 13.2 (2.33) 0.002
*
n=58
**
n=38
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